May 15, 2024 7:57am

A lean aftermarket expecting overall and core consumer prices rose 3.4% in April after a 0.4% gain in March

Attention remains laser-focused on week’s busy economic calendar; there’s still a bit of hesitation in front of inflation data to really see the reality of the markets and the cell and gene therapy sector’s ability or capacity to move directionally

A daily analytic discipline is constructed by period updates and specific warnings of emerging situations

Never leave an investor uninformed

 

Remember that overnight and pre-open actions’ futures and global markets doesn't necessarily translate into actual trading in the today’s market session.

Framing the main takeaway … pricing, volume and volatility; it also includes what happened or will happen beyond the headline which shapes today’s potential sector response as seen by RM

 

Wednesday: The pre-open Dow futures are UP +47% or (+186 points), the S&P futures are UP +0.60% or (+31 points) as the Nasdaq futures are UP +62% or (+114 points)

Stock futures were mixed, barely and challenged Wednesday,  

European markets were slightly higher,

Asia-Pacific markets were mixed.

 

Henry’omics:

We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies …

Tuesday: The Dow closed UP +126.60 points or +0.32%, the S&P closed UP +25.26 points or +0.48 % while the Nasdaq closed UP +122.94 points or +0.75%

Economic Data Docket: Consumer Price Index, month-over-month, April (+0.4% expected, +0.4% previously);

  • Core CPI, month-over-month, April (+0.3% expected, +0.4% previously);
  • CPI, year-over-year, April (+3.4% expected, +3.5% previously);
  • Core CPI, year-over-year, April (+3.6% expected, +3.8% previously);
  • Real average hourly earnings, year-over-year, April (+0.6% previously);
  • MBA Mortgage Applications, week ending May 10 (+2.6%); Retail sales, month-over-month, April (+0.4%% expected, +0.7% previously);
  • Retail sales ex auto and gas, April (+0.1% expected, +1% previously);
  • NAHB housing market index, May (51 expected, 51 previously)

 

Monday night’s RegMed Investors (RMi) Closing Bell: “up and some astray as sector speculative rises. Even as inflation expectations increase.” … https://www.regmedinvestors.com/articles/13458

 

Q2/24:  May – 7 positive and 3 negative closes

  • April - 16 negative and 6 positive closes

 

Companies in my headlights – It’s your decision; I provide ideas and context:

I post about “indication intelligence” devoting my time to collection and analysis of information to assist investors with insight into sector vulnerabilities and strengths. A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

 

Yet again, I am passing on forecasting the daily indications is focused on inflation-oriented CPI and Retail sales, NAHB housing market index and MBA Mortgage Applications “numbers” the aftermarket fluctuated as the pre-open waits for the all-clear alarm, …  it is still a mix of ups, downs and just unknowns.

 

The BOTTOM LINE: The Q1/24 earnings season is winding down as 29 of my 35 have reported, but investors will see a few more reports this week

After hours reporting:

  • Brainstorm Cell Therapeutics (BCLI) reported a Q1/24 net loss of -$3.4 M or -0.05 per share with a cash position of $1 M and a runway until Q2/24

Pick your poison, trade any ups, buy into some bottoms, build cash position; as buying the lows - they can eventually be the overbought through unbridled speculation and then trade again.

  • Indexes are trading around record highs after solid advances.
  • Sector equities have looked even better in Q2/24 with 7 positive and 3 negative closes, so far; as compared to April’s 16 negative and 6 positive closes
  • The 10-year Treasury yield fell 3.5 basis points to 4.44%, reversing lower from an intraday peak of 4.53%.

RegMed Investors (RMi) - Q1/24 Cell and Gene Therapy Earnings Scorecard Results … https://www.regmedinvestors.com/articles/11628

  • Investors must eye-ball earnings results, runways, and forecasts. Missed EPS and revenue indications usually signify the changing landscape of short and near-term prospects and trends.
  • With this in mind, missed estimates reveal a sign of pessimism about sector company's share pricing outlook other than possible pop tarts of clinical results or potential partnership or acquisition actions.
  • My on-going theses suggests that estimates have a direct relationship with upcoming stock price performance.

 

Welcome to my world of defining the “grey’ in our universe!

  • Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and facts are its product; I can always be WRONG but … I am mostly EARLY!”
  • The sector is what it is, until it isn’t and even then, it doesn’t seem to be… as NOT much changes as the sector’s share pricing rides the waves of volatility, algorithms, electronic trading and short covering.
  • Never forget, one of my usual lines. “The sector is … still what it is, until it isn’t and even then, it doesn’t seem to be … that is after taking a deep breath and holding it.”
  • I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors could hold or have positions securities referred to in this publication and he will NOTIFY investors of holdings.